Leading immunoassay specialist, BBI Solutions, will demonstrate how its lateral flow software is making point-of-care testing (POCT) more accurate, efficient and easier to use than ever before at the world’s largest laboratory medicine tradeshow, American Association for Clinical Chemistry (AACC) exhibition, this summer.
BBI’s mobile arm, Novarum™, will launch a demonstrator app that can read the results of an imitated malaria test on stand 4254 at the AACC Clinical Lab Expo, which runs from 4th-8th August in California. The app is designed to demonstrate to potential customers how mobile technology can remove complexities from lateral flow testing to enable healthcare professionals or patients to deliver lab quality results in the field.
Novarum’s innovative mobile technology mitigates the risks identified around lateral flow by the Clinical Laboratory Improvement Amendments (CLIA), which establishes quality standards for all laboratory testing to ensure the accuracy, reliability and timeliness of patient test results.
CLIA Waived tests must demonstrate that a device is simple to use, has low risk to public health, and that an untrained person can get accurate results by reading the instructions.
The 14-strong delegation representing BBI Solutions will join global leaders in clinical chemistry, in vitro diagnostics, lab management and other areas of breaking science in laboratory medicine to network and explore some of the industry’s latest technological advances.
The company will demonstrate every aspect of its immunoassay development - feasibility and planning, reagent supply and manufacturing, custom antibody development, custom conjugations, lateral flow development and manufacturing as well as Novarum’s smartphone reader capability which enables immediate, point-of-care diagnosis.
Novarum is an easy-to-use mobile app enabling rapid point-of-care testing, using just a smartphone. Novarum’s technology accurately interprets the results of lateral flow assays whilst offering test choreography and tracking disease outbreaks, providing clients with a competitive advantage within the diagnostic landscape.
John Hanson, Chief Commercial Officer at BBI Solutions, said: “This is an exciting opportunity to, once again, showcase BBI Solutions’ comprehensive suite of capabilities at the AACC expo. We’re particularly excited to be launching our demo app at the event this year, which enables us to demonstrate every aspect of Novarum’s capability that a potential customer could include in a custom-built app.
“We want to help our customers envision what it would be like for the healthcare professional or patient using the test and to highlight how Novarum’s software mitigates the risks identified around lateral flow testing.
“We’re looking forward to joining some of the industry’s biggest names at the tradeshow and promoting BBI Solutions’ exciting proposition on a global stage.”
For more information about BBI Solutions, please visit www.bbisolutions.com or join us on booth 4254 at AACC.
This release was issued by Influential on behalf of BBI Solutions. For more information, please contact Ruth Cobban or Steph Bocking on 0151 239 5000 or email: firstname.lastname@example.org email@example.com
About BBI Solutions
BBI Solutions is a leading manufacturer of biological reagents and finished test platforms for the in-vitro diagnostics market. BBI is a global business with manufacturing sites spanning three continents.
Our range of raw materials includes human antigens, antibodies, serum and plasma products and clinical chemistry enzymes. We manufacture world renowned labels for lateral flow, ELISA assay and biosensors, including our gold nanoparticles and glucose oxidase.
BBI Solutions offers lateral flow development and manufacturing services with a core focus on antibody development, gold conjugation, lateral flow test manufacture and smartphone reader solutions.
BBI Solutions is part of the BBI Group. www.bbisolutions.com